<DOC>
	<DOCNO>NCT02087696</DOCNO>
	<brief_summary>The purpose project evaluate efficacy Tocilizumab ( TCZ ) give monotherapy patient active rheumatoid arthritis ( RA ) accord EULAR response 24 week treatment initiation . The study design intervention study , uncontrolled , multicenter , prospective , 32-weeks , two cohort patient poor compliance contraindication intolerance methotrexate . One cohort naive previous biological therapy one treat previously biological treatment .</brief_summary>
	<brief_title>Uncontrolled Study Evaluate Efficacy Tocilizumab Patients With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Patients ability willing provide write informed consent comply requirement study protocol . Patients active moderate severe rheumatoid arthritis , accord 1987 ACR criterion , diagnose least 6 month inclusion . 18 year old old DAS28 index great 3.2 baseline . If patient receive corticosteroid dose â‰¤ 10 mg prednisone ( equivalent ) patient must stable least one month previous initiate treatment Tocilizumab ( day 1 ) . Patients may treat nonsteroidal antiinflammatory drug ( NSAIDs ) stable dos previous month inclusion . Patients receive outpatient treatment . Women childbearing potential men childbearing potential partner may participate study use reliable contraception ( eg barrier method [ patient partner ] , oral patch contraceptive , spermicide barrier method intrauterine device ) study period least 3 month receive last dose Tocilizumab . In woman childbearing potential pregnancy test must negative screen visit baseline . Patients methotrexate monotherapy combine treatment biological agent , patient biological treatment monotherapy , show ever show intolerance poor compliance safety issue methotrexate . Patients judge candidate biological monotherapy researcher , without exclude previous use diseasemodifying antirheumatic drug ( DMARDs ) different methotrexate . Patients peripheral venous access . Patients previous failure two biological treatment . Previous treatment Tocilizumab time baseline visit . Treatment agent research four week previous screen visit ( equivalent period five halflives ) Considering long period . Previous treatment cell depletion therapy , include experimental treatment approve agent , example : CAMPATH , antiCD4 , antiCD5 , antiCD3 , antiCD19 antiCD20 ) . Treatment intravenous gammaglobulin plasmapheresis 6 month previous baseline visit . Intraarticular parenteral corticosteroid within 4 week previous baseline visit . Immunization live / attenuate vaccine previous 4 week baseline visit . Previous treatment alkylating agent chlorambucil , full lymphoid irradiation . History severe allergic anaphylactic reaction human , humanized murine , monoclonal antibody . Evidence serious uncontrolled concomitant disease : cardiovascular , nervous system , lung ( include chronic obstructive pulmonary disease ) , renal , hepatic , endocrine ( include uncontrolled diabetes mellitus ) gastrointestinal . History diverticulitis , diverticulosis require treatment antibiotic , chronic low gastrointestinal ulcer disease , Crohn 's disease , ulcerative colitis lower gastrointestinal symptomatic condition could predispose perforation . Known active Infections , history know recur infection : Mycobacterial , fungal , viral bacterial type ( include , limited , tuberculosis , atypical mycobacterial disease , hepatitis B C , herpes zoster , exclude nail bed fungal infection ) . Any major episode infection require hospitalization treatment intravenous antibiotic within 4 week previous screen visit oral antibiotic within 2 week previous screen visit . Active tuberculosis require treatment past year . Latent tuberculosis screen perform patient accord Spanish Society Rheumatology/Spanish Agency Medicines Health Products ( SER/AEMPS ) guideline . Patients treat tuberculosis without recurrence past 3 year exclude . Ongoing liver disease determine principal investigator . Evidence active malignancy , malignancy diagnose previous 10 year ( include solid hematologic tumor , except basal cell carcinoma squamous cell skin remove cured situ cervix carcinoma ) , breast cancer diagnose previous 20 year . Pregnant breastfeed woman . Patients reproductive potential unwilling use effective contraception . History alcoholism , drug abuse addiction previous year screen visit . Neuropathies painful condition may interfere pain assessment . Serum creatinine &gt; 1,4 mg/dl ( 124 mol/l ) woman &gt; 1.6 mg/dl ( 141 mol/l ) men . Alanine aminotransferase aspartate aminotransferase &gt; 1.5 time upper limit normal . Total bilirubin great upper limit normal . Platelet count minor 100 x 10^9/l ( 100.000/mm3 ) . Hemoglobin minor 85 g/L ( &lt; 8,5 g/dL , 5,3 mmol/L ) . Leukocytes minor 3,0 x 10^9/L ( 3000/mm3 ) . Neutrophils , absolute value minor 2,0 x 10^9/L ( 2000/mm3 ) . Lymphocytes , absolute value minor 0,5 x 10^9 /L ( 500/mm3 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Arthritis , Rheumatoid</keyword>
	<keyword>methotrexate</keyword>
	<keyword>intolerance</keyword>
	<keyword>poor compliance</keyword>
	<keyword>contraindication</keyword>
	<keyword>Tocilizumab</keyword>
	<keyword>monotherapy</keyword>
</DOC>